391 related articles for article (PubMed ID: 6357431)
1. Mammary tumor growth inhibition in C3H/He mice by long-term Bacillus Calmette-Guérin immunoprophylaxis versus enhancement by primary Bacillus Calmette-Guérin therapy.
Vaage J
Cancer Res; 1983 Dec; 43(12 Pt 1):5778-82. PubMed ID: 6357431
[TBL] [Abstract][Full Text] [Related]
2. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin.
Joraku A; Homhuan A; Kawai K; Yamamoto T; Miyazaki J; Kogure K; Yano I; Harashima H; Akaza H
BJU Int; 2009 Mar; 103(5):686-93. PubMed ID: 19040525
[TBL] [Abstract][Full Text] [Related]
3. Preoperative intralesional Bacillus Calmette-Guérin for mammary adenocarcinoma in rats.
Lee YT
Cancer Res; 1977 Oct; 37(10):3679-83. PubMed ID: 908015
[TBL] [Abstract][Full Text] [Related]
4. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
[TBL] [Abstract][Full Text] [Related]
5. Effects of methanol extraction residue and therapeutic irradiation against established isografts and simulated local recurrence of mammary carcinomas.
Yron I; Cohen D; Robinson E; Haber M; Weiss DW
Cancer Res; 1975 Jul; 35(7):1779-90. PubMed ID: 1093676
[TBL] [Abstract][Full Text] [Related]
6. Long term protection in bladder cancer following intralesional immunotherapy.
Reichert DF; Lamm DL
J Urol; 1984 Sep; 132(3):570-3. PubMed ID: 6381762
[TBL] [Abstract][Full Text] [Related]
7. Effect of Myobacterium bovis (strain Bacillus Calmette-Guérin) on macrophage production by the bone marrow of tumor-bearing mice.
Fisher B; Taylor S; Levine M; Saffer E; Fisher ER
Cancer Res; 1974 Jul; 34(7):1668-70. PubMed ID: 4599359
[No Abstract] [Full Text] [Related]
8. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity.
Shapiro A; Ratliff TL; Oakley DM; Catalona WJ
Cancer Res; 1983 Apr; 43(4):1611-5. PubMed ID: 6339040
[TBL] [Abstract][Full Text] [Related]
9. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin.
Ratliff TL; Palmer JO; McGarr JA; Brown EJ
Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453
[TBL] [Abstract][Full Text] [Related]
10. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
[TBL] [Abstract][Full Text] [Related]
11. Systemic antitumor activity of Bacillus Calmette Guerin and purified protein derivatives against tumors in mice having tuberculin allergy.
Abe S; Saito M; Yamazaki M; Mizuno D; Tsumita T
Jpn J Exp Med; 1978 Oct; 48(5):455-7. PubMed ID: 372638
[No Abstract] [Full Text] [Related]
12. Comparative antitumor effects of Corynebacterium parvum, Bordetella pertussis, Bacillus Calmette-Guérin, and levamisole alone or in combination with cyclophosphamide in the CaD2 murine mammary adenocarcinoma system.
Purnell DM; Bartlett GL; Kreider JW; Biro TG; Kontra J
Cancer Res; 1979 Dec; 39(12):4838-42. PubMed ID: 498111
[TBL] [Abstract][Full Text] [Related]
13. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of Bacillus Calmette-Guérin-induced suppression of metastases in a poorly immunogenic fibrosarcoma.
Liotta LA; Kleinerman J; Saidel GM
Cancer Res; 1976 Sep; 36(9 pt.1):3255-9. PubMed ID: 788897
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of C3H/He mouse mammary tumor growth by combined treatment with cyclophosphamide and polyadenylic-polyuridylic acid.
Youn JK; Lacour F; Hue G
Cancer Res; 1982 Nov; 42(11):4706-11. PubMed ID: 7127305
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of Corynebacterium parvum, Brucella abortus extract, Bacillus Calmette-Guérin, glucan, levamisole, and tilorone with or without cyclophosphamide on tumor growth, macrophage production, and macrophage cytotoxicity in a murine mammary tumor model.
Fisher B; Gebhardt M
Cancer Treat Rep; 1978 Nov; 62(11):1919-30. PubMed ID: 728912
[TBL] [Abstract][Full Text] [Related]
17. Conditions for effective Bacillus Calmette-Guérin immunotherapy of postsurgical metastases of 13762A rat mammary adenocarcinoma.
Kreider JW; Bartlett GL; Boyer CM; Purnell DM
Cancer Res; 1979 Mar; 39(3):987-92. PubMed ID: 427785
[TBL] [Abstract][Full Text] [Related]
18. Treatment of the mouse Lewis tumor by the association of radiotherapy and immunotherapy with Bacillus Calmette-Guérin.
Dubois JB; Serrou B
Cancer Res; 1976 May; 36(5):1731-4. PubMed ID: 773530
[TBL] [Abstract][Full Text] [Related]
19. Defining bacillus Calmette-Guerin refractory superficial bladder tumors.
Herr HW; Dalbagni G
J Urol; 2003 May; 169(5):1706-8. PubMed ID: 12686813
[TBL] [Abstract][Full Text] [Related]
20. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI
Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
